Skip to main content
. 2015 Oct 3;17:134. doi: 10.1186/s13058-015-0642-8

Table 1.

Patient and tumor characteristics

Characteristic Values (n = 56 patients)
Age
 Median, range 40 (23–74)
Tumor stage
 1 5 (9)
 2 40 (71)
 3 7 (13)
 4 4 (7)
Nodal stage
 Lymph nodes negative 19 (34)
 Lymph nodes positive 37 (66)
Grade
 II 18 (32)
 III 34 (61)
 Not determined 4 (7)
Chemotherapy
 6 × dose dense doxorubicin/cyclophosphamide 43 (77)
 3 × dose dense doxorubicin/cyclophosphamide, 3 × docetaxel/capecitabine 5 (9)
 4 × dose dense doxorubicin/cyclophosphamide, 2 × cyclophosphamide/thiotepa/carboplatin 8 (14)
BRCA germline mutation status (Sanger sequencing)
BRCA1 mutation 10 (18)
BRCA2 mutation 2 (4)
 Wildtype 39 (70)
 Not determined 5 (9)
BRCA1 promoter methylation
 No BRCA1 methylation 39 (70)
BRCA1 methylation 17 (30)
Response breast and lymph nodes
 No pathological complete remission 31 (55)
 Pathological complete remission 25 (45)
Relapse
 No relapse 47 (84)
 Relapse 9 (16)

Values are n (%) unless stated otherwise